Biopharma execs cheer Supreme Court for upholding FDA authority in abortion pill case

On Thursday, the Supreme Court rejected an effort by anti-abortion doctors to bar the mailing of the abortion pill mifepristone. The case presented a serious challenge to the Food and Drug Administration’s authority to regulate medicines.

Biopharmaceutical companies and doctors organizations applauded the ruling but also warned that threats to mifepristone access are far from over. 

Daphne Zohar, Seaport Therapeutics CEO:

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In